NurExone logo2.png
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02 févr. 2024 16h05 HE | NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
Logo.jpg
Ecological Momentary Assessment Market To Reach USD 59.9 Million By 2032, Says DataHorizzon Research
18 janv. 2024 07h10 HE | DataHorizzon Research
Fort Collins, Colorado, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The Ecological Momentary Assessment Market was valued at USD 12.1 Million in 2022 and is anticipated to grow CAGR at 17.4% to reach USD 59.9...
OpsMx Logo.png
OpsMx Named to First Annual EMA Allstars 2024 List
10 janv. 2024 16h21 HE | OpsMx
SUNNYVALE, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- OpsMx, the leader in secure software delivery, today announced it is featured in the inaugural 2024 EMA Allstars list in the “DevSecOps Platform...
Logo.jpg
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
13 nov. 2023 09h00 HE | Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Stonebranch Named a
Stonebranch Named a Value Leader in the 2023 EMA Radar™ Report for Workload Automation and Orchestration
02 oct. 2023 09h00 HE | Stonebranch
ALPHARETTA, Ga., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Stonebranch, a leading provider of service orchestration and automation solutions, announced today that it has been named a Value Leader in the...
AB Science provides
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
18 sept. 2023 12h05 HE | AB Science
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS ...
AB Science fait une
AB Science fait une mise au point sur le calendrier de l’EMA concernant l'examen de la demande d'autorisation de mise sur le marché du masitinib dans la SLA
18 sept. 2023 12h05 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LE CALENDRIER DE L'AGENCE EUROPÉENNE DES MÉDICAMENTS CONCERNANT L'EXAMEN DE LA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ DU MASITINIB DANS LA...
Pfizer und BioNTech
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron XBB.1.5 angepassten COVID-19-Impfstoff in der Europäischen Union
30 août 2023 10h00 HE | BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron XBB.1.5-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen Daten, die...
Pfizer and BioNTech
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
30 août 2023 10h00 HE | BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical data...
InflaRx on large white.jpg
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
30 août 2023 07h30 HE | InflaRx N.V.
MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at...